Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Gerlach M, Bartoszyk GD, Riederer P, Dean O, van den Buuse M.

J Neural Transm (Vienna). 2011 Dec;118(12):1733-42. doi: 10.1007/s00702-010-0571-8. Epub 2011 Jan 21.

PMID:
21253782
2.

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.

Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.

Parkinsonism Relat Disord. 2009 Jul;15(6):445-52. doi: 10.1016/j.parkreldis.2008.11.001. Epub 2009 Feb 3.

PMID:
19196540
3.

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.

Neuropharmacology. 2015 Jun;93:52-67. doi: 10.1016/j.neuropharm.2015.01.012. Epub 2015 Jan 31.

PMID:
25645393
4.

The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.

Mela F, Millan MJ, Brocco M, Morari M.

Neuropharmacology. 2010 Feb;58(2):528-36. doi: 10.1016/j.neuropharm.2009.08.017. Epub 2009 Sep 4.

PMID:
19733554
5.

L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.

Mo J, Zhang H, Yu LP, Sun PH, Jin GZ, Zhen X.

Neurobiol Aging. 2010 Jun;31(6):926-36. doi: 10.1016/j.neurobiolaging.2008.06.017. Epub 2008 Aug 15.

PMID:
18707801
6.

The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.

Eskow KL, Gupta V, Alam S, Park JY, Bishop C.

Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):306-14. Epub 2007 May 13.

PMID:
17553556
7.

The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.

Gerlach M, Halley P, Riederer P, van den Buuse M.

J Neural Transm (Vienna). 2013 Jan;120(1):31-6. doi: 10.1007/s00702-012-0818-7. Epub 2012 May 17.

PMID:
22592937
8.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
9.

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A.

Exp Neurol. 2015 Sep;271:335-50. doi: 10.1016/j.expneurol.2015.05.021. Epub 2015 May 30.

PMID:
26037043
10.

Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.

Paquette MA, Martinez AA, Macheda T, Meshul CK, Johnson SW, Berger SP, Giuffrida A.

Eur J Neurosci. 2012 Nov;36(9):3224-34. doi: 10.1111/j.1460-9568.2012.08243.x. Epub 2012 Aug 3.

11.

MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.

Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD.

Eur J Neurosci. 2006 May;23(10):2669-76.

PMID:
16817869
12.

Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD.

J Neurosci Res. 2009 May 15;87(7):1645-58. doi: 10.1002/jnr.21978.

13.

Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.

Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'isola R, Katzman AC, Bishop C.

Neuropharmacology. 2014 Feb;77:1-8. doi: 10.1016/j.neuropharm.2013.09.017. Epub 2013 Sep 22.

14.

Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.

Mahmoudi J, Nayebi AM, Samini M, Reyhani-Rad S, Babapour V.

Pharmacol Rep. 2011;63(4):908-14.

15.

The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.

McCreary AC, Varney MA, Newman-Tancredi A.

Neuropharmacology. 2016 Jun;105:651-660. doi: 10.1016/j.neuropharm.2016.01.013. Epub 2016 Jan 9.

PMID:
26777281
16.

Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Gerlach M, Beck J, Riederer P, van den Buuse M.

J Neural Transm (Vienna). 2011 Dec;118(12):1727-32. doi: 10.1007/s00702-010-0570-9. Epub 2011 Jan 28.

PMID:
21274579
17.

Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.

Shin E, Garcia J, Winkler C, Björklund A, Carta M.

Neurobiol Dis. 2012 Sep;47(3):393-406. doi: 10.1016/j.nbd.2012.03.038. Epub 2012 Apr 12.

PMID:
22579773
18.

The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.

Thornton E, Hassall MM, Corrigan F, Vink R.

Parkinsonism Relat Disord. 2014 May;20(5):508-13. doi: 10.1016/j.parkreldis.2014.02.008. Epub 2014 Feb 20.

PMID:
24637127
19.

Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Marin C, Aguilar E, Rodríguez-Oroz MC, Bartoszyk GD, Obeso JA.

Psychopharmacology (Berl). 2009 Jun;204(2):241-50. doi: 10.1007/s00213-008-1452-9. Epub 2009 Jan 22.

PMID:
19159919
20.

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.

Bézard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.

Neurosci Res. 2013 Dec;77(4):242-6. doi: 10.1016/j.neures.2013.10.002. Epub 2013 Oct 14.

PMID:
24135129

Supplemental Content

Support Center